BACKGROUND: Exacerbations of asthma are associated with substantial morbidity and mortality and with considerable use of health care resources. Preventing exacerbations remains an important goal of therapy. There is evidence that eosinophilic inflammation of the airway is associated with the risk of exacerbations. METHODS: We conducted a randomized, double-blind, placebo-controlled, parallel-group study of 61 subjects who had refractory eosinophilic asthma and a history of recurrent severe exacerbations. Subjects received infusions of either mepolizumab, an anti-interleukin-5 monoclonal antibody (29 subjects), or placebo (32) at monthly intervals for 1 year. The primary outcome measure was the number of severe exacerbations per subject during the 50-week treatment phase. Secondary outcomes included a change in asthma symptoms, scores on the Asthma Quality of Life Questionnaire (AQLQ, in which scores range from 1 to 7, with lower values indicating more severe impairment and a change of 0.5 unit considered to be clinically important), forced expiratory volume in 1 second (FEV(1)) after use of a bronchodilator, airway hyperresponsiveness, and eosinophil counts in the blood and sputum. RESULTS:Mepolizumab was associated with significantly fewer severe exacerbations than placebo over the course of 50 weeks (2.0 vs. 3.4 mean exacerbations per subject; relative risk, 0.57; 95% confidence interval [CI], 0.32 to 0.92; P=0.02) and with a significant improvement in the score on the AQLQ (mean increase from baseline, 0.55 vs. 0.19; mean difference between groups, 0.35; 95% CI, 0.08 to 0.62; P=0.02). Mepolizumab significantly lowered eosinophil counts in the blood (P<0.001) and sputum (P=0.002). There were no significant differences between the groups with respect to symptoms, FEV(1) after bronchodilator use, or airway hyperresponsiveness. The only serious adverse events reported were hospitalizations for acute severe asthma. CONCLUSIONS:Mepolizumab therapy reduces exacerbations and improves AQLQ scores in patients with refractory eosinophilic asthma. The results of our study suggest that eosinophils have a role as important effector cells in the pathogenesis of severe exacerbations of asthma in this patient population. (Current Controlled Trials number, ISRCTN75169762.) 2009 Massachusetts Medical Society
RCT Entities:
BACKGROUND: Exacerbations of asthma are associated with substantial morbidity and mortality and with considerable use of health care resources. Preventing exacerbations remains an important goal of therapy. There is evidence that eosinophilic inflammation of the airway is associated with the risk of exacerbations. METHODS: We conducted a randomized, double-blind, placebo-controlled, parallel-group study of 61 subjects who had refractory eosinophilic asthma and a history of recurrent severe exacerbations. Subjects received infusions of either mepolizumab, an anti-interleukin-5 monoclonal antibody (29 subjects), or placebo (32) at monthly intervals for 1 year. The primary outcome measure was the number of severe exacerbations per subject during the 50-week treatment phase. Secondary outcomes included a change in asthma symptoms, scores on the Asthma Quality of Life Questionnaire (AQLQ, in which scores range from 1 to 7, with lower values indicating more severe impairment and a change of 0.5 unit considered to be clinically important), forced expiratory volume in 1 second (FEV(1)) after use of a bronchodilator, airway hyperresponsiveness, and eosinophil counts in the blood and sputum. RESULTS:Mepolizumab was associated with significantly fewer severe exacerbations than placebo over the course of 50 weeks (2.0 vs. 3.4 mean exacerbations per subject; relative risk, 0.57; 95% confidence interval [CI], 0.32 to 0.92; P=0.02) and with a significant improvement in the score on the AQLQ (mean increase from baseline, 0.55 vs. 0.19; mean difference between groups, 0.35; 95% CI, 0.08 to 0.62; P=0.02). Mepolizumab significantly lowered eosinophil counts in the blood (P<0.001) and sputum (P=0.002). There were no significant differences between the groups with respect to symptoms, FEV(1) after bronchodilator use, or airway hyperresponsiveness. The only serious adverse events reported were hospitalizations for acute severe asthma. CONCLUSIONS:Mepolizumab therapy reduces exacerbations and improves AQLQ scores in patients with refractory eosinophilic asthma. The results of our study suggest that eosinophils have a role as important effector cells in the pathogenesis of severe exacerbations of asthma in this patient population. (Current Controlled Trials number, ISRCTN75169762.) 2009 Massachusetts Medical Society
Authors: M J Leckie; A ten Brinke; J Khan; Z Diamant; B J O'Connor; C M Walls; A K Mathur; H C Cowley; K F Chung; R Djukanovic; T T Hansel; S T Holgate; P J Sterk; P J Barnes Journal: Lancet Date: 2000 Dec 23-30 Impact factor: 79.321
Authors: Patrick Flood-Page; Cheri Swenson; Isidore Faiferman; John Matthews; Michael Williams; Lesley Brannick; Douglas Robinson; Sally Wenzel; William Busse; Trevor T Hansel; Neil C Barnes Journal: Am J Respir Crit Care Med Date: 2007-09-13 Impact factor: 21.405
Authors: Pranab Haldar; Ian D Pavord; Ruth H Green; Dominic E Shaw; Michael A Berry; Michael Thomas; Christopher E Brightling; Andrew J Wardlaw Journal: Am J Respir Crit Care Med Date: 2008-05-14 Impact factor: 21.405
Authors: Mario Castro; Sean B Fain; Eric A Hoffman; David S Gierada; Serpil C Erzurum; Sally Wenzel Journal: J Allergy Clin Immunol Date: 2011-06-02 Impact factor: 10.793
Authors: Michael E Wechsler; Praveen Akuthota; David Jayne; Paneez Khoury; Amy Klion; Carol A Langford; Peter A Merkel; Frank Moosig; Ulrich Specks; Maria C Cid; Raashid Luqmani; Judith Brown; Stephen Mallett; Richard Philipson; Steve W Yancey; Jonathan Steinfeld; Peter F Weller; Gerald J Gleich Journal: N Engl J Med Date: 2017-05-18 Impact factor: 91.245
Authors: W Gerald Teague; Brenda R Phillips; John V Fahy; Sally E Wenzel; Anne M Fitzpatrick; Wendy C Moore; Annette T Hastie; Eugene R Bleecker; Deborah A Meyers; Stephen P Peters; Mario Castro; Andrea M Coverstone; Leonard B Bacharier; Ngoc P Ly; Michael C Peters; Loren C Denlinger; Sima Ramratnam; Ronald L Sorkness; Benjamin M Gaston; Serpil C Erzurum; Suzy A A Comhair; Ross E Myers; Joe Zein; Mark D DeBoer; Anne-Marie Irani; Elliot Israel; Bruce Levy; Juan Carlos Cardet; Wanda Phipatanakul; Jonathan M Gaffin; Fernando Holguin; Merritt L Fajt; Shean J Aujla; David T Mauger; Nizar N Jarjour Journal: J Allergy Clin Immunol Pract Date: 2017-08-31
Authors: Elizabeth A Kelly; Stephane Esnault; Lin Ying Liu; Michael D Evans; Mats W Johansson; Sameer Mathur; Deane F Mosher; Loren C Denlinger; Nizar N Jarjour Journal: Am J Respir Crit Care Med Date: 2017-12-01 Impact factor: 21.405